The VEGFA Polyclonal Antibody (CAB5708) is a valuable tool for researchers studying vascular endothelial growth factor A (VEGFA), a key regulator of angiogenesis and vascular permeability. This antibody, produced in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blot applications. By specifically binding to the VEGFA protein, this antibody enables precise detection and analysis in various cell types, making it ideal for studies in cancer biology, vascular biology, and angiogenesis research.VEGFA is a crucial factor in promoting the formation of new blood vessels, a process that is essential for tumor growth and metastasis.
By targeting VEGFA, researchers can explore its role in tumor angiogenesis, tumor progression, and potential therapeutic strategies for cancer treatment. Additionally, VEGFA is implicated in various other pathological conditions such as diabetic retinopathy, macular degeneration, and inflammatory disorders, making this antibody a versatile tool for investigating a wide range of biomedical research topics.
Product Name:
VEGF Rabbit Polyclonal Antibody
SKU:
CAB5708
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Mouse,Rat
Immunogen:
A synthetic peptide corresponding to a sequence within amino acids 50-147 of human VEGFA (NP_001165099.1).
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines.
Purification Method:
Affinity purification
Gene ID:
7422
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3.
Western blot analysis of extracts of various cell lines, using VEGFA antibody (CAB5708) at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25μg per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 180s.
